文献速递医学人工智能与信息学临床试验与 GCP真实世界研究与卫生经济

基于人工智能的骨关节炎患者手术与否个体化临床决策支持系统:单中心、平行组、非劣效随机对照试验研究方案

An AI-based patient-specific clinical decision support system for OA patients choosing surgery or not: study protocol for a single-centre, parallel-group, non-inferiority randomised controlled trial.
PubMed 文献 · Trials · 2023-01-12

该研究为单中心、平行组、非劣效随机对照试验方案,旨在探讨常规诊疗是否非劣于ERVIN.2支持的诊疗,并评估ERVIN.2是否增强临床决策支持及其成本效果。对照组接受常规诊疗,干预组额外获得基线评分及预测的牛津髋/膝关节评分和健康相关生活质量。

要点

  • 研究为单中心、平行组、非劣效随机对照试验,比较常规诊疗与ERVIN.2支持的诊疗。
  • 干预组额外获得基线评分及预测的牛津髋/膝关节评分和健康相关生活质量。
  • 主要目标为探讨常规诊疗是否非劣于ERVIN.2支持的诊疗。

核心结论

  • 该研究将提供关于ERVIN.2是否增强临床决策支持、临床效果及该人工智能系统成本效果的知识。

研究设计与样本

  • 单中心、非劣效、随机对照、两臂平行组设计,将按照CONSORT指南报告。
  • 对照组接受常规诊疗,干预组额外获得基线评分及预测的牛津髋/膝关节评分和健康相关生活质量。
  • 将采用医院视角、1年时间 horizon、以EQ-5D-3L估算效果,与试验同步进行成本-效用分析,结果以每获得一个QALY的成本呈现。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究设计不允许对 surgeons 设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteoarthritis (OA) affects 20% of the adult Danish population, and the financial burden to society amounts to DKK 4.6 billion annually. Research suggests that up to 75% of surgical patients could have postponed an operation and managed with physical training. ERVIN.2 is an artificial intelligence (AI)-based clinical support system that addresses this problem by enhancing patient involvement in decisions concerning surgical knee and hip replacement. However, the clinical outcomes and cost-effectiveness of using such a system are scantily documented. OBJECTIVE: The primary objective is to investigate whether the usual care is non-inferior to ERVIN.2 supported care. The second objective is to determine if ERVIN.2 enhances clinical decision support and whether ERVIN.2 supported care is cost-effective. METHODS: This study used a single-centre, non-inferiority, randomised controlled in a two-arm parallel-group design. The study will be reported in compliance with CONSORT guidelines. The control group receives the usual care. As an add-on, the intervention group have access to baseline scores and predicted Oxford hip/knee scores and HRQoL for both the surgical and the non-surgical trajectory. A cost-utility analysis will be conducted alongside the trial using a hospital perspective, a 1-year time horizon and effects estimated using EQ-5D-3L. Results will be presented as cost per QALY gain. DISCUSSION: This study will bring knowledge about whether ERVIN.2 enhances clinical decision support, clinical effects, and cost-effectiveness of the AI system. The study design will not allow for the blinding of surgeons. TRIAL REGISTRATION: ClinicalTrials.gov NCT04332055 . Registered on 2 April 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kastrup N, Bjerregaard HH, Laursen M, et al. An AI-based patient-specific clinical decision support system for OA patients choosing surgery or not: study protocol for a single-centre, parallel-group, non-inferiority randomised controlled trial. Trials. 2023. PMID: 36635747. doi:10.1186/s13063-022-07039-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。